Skip to Main Content
DownloadHi-Res Photo

Marcus Bosenberg, MD, PhD

Professor of Dermatology, Pathology, and Immunobiology; Co-Leader, Genetics, Genomics and Epigenetics, Yale Cancer Center; Interim Director, Yale Center for Immuno-Oncology; Director, Yale SPORE in Skin Cancer

Contact Information

Marcus Bosenberg, MD, PhD

Office Location

Mailing Address

  • Dermatology

    PO Box 208059, 333 Cedar Street

    New Haven, CT, 06520-8059

    United States

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Directs a National Cancer Institute funded melanoma research laboratory with interests in several aspects of melanoma biology including the cell biology and genetics of metastasis, tumor immunology, prognostic and diagnostic markers and development of new therapeutic agents.

Specialized Terms: Tumor immunology; Melanoma models; Melanocytic neoplasms; Genodermatoses

Extensive Research Description

Directs a National Cancer Institute funded melanoma research laboratory with interests in several aspects of melanoma biology including the cell biology and genetics of metastasis, prognostic and diagnostic markers and development of new therapeutic agents.

Coauthors

Research Interests

Cell Biology; Dermatology; Melanoma; Neoplasm Metastasis; Pathology

Selected Publications

  • Genotype-selective combination therapies for melanoma identified by high-throughput drug screening.Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, Bacchiocchi A, Koo A, Haskins JW, Bosenberg MW, Stern DF. Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discovery 2013, 3:52-67.
  • β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.Damsky WE, Curley DP, Santhanakrishnan M, Rosenbaum LE, Platt JT, Gould Rothberg BE, Taketo MM, Dankort D, Rimm DL, McMahon M, Bosenberg M. β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell 2011, 20:741-54.
  • Characterization of melanoma cells capable of propagating tumors from a single cell.Held MA, Curley DP, Dankort D, McMahon M, Muthusamy V, Bosenberg MW. Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Research 2010, 70:388-97.
  • Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, You MJ, DePinho RA, McMahon M, Bosenberg M. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nature Genetics 2009, 41:544-52.
  • mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.Damsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, Davies MA, Dankort D, McMahon M, Merlino G, Bardeesy N, Bosenberg M. mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell 2015, 27:41-56.
  • DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR.Micevic G, Muthusamy V, Damsky W, Theodosakis N, Liu X, Meeth K, Wingrove E, Santhanakrishnan M, Bosenberg M. DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR. Cell Reports 2016, 14:2180-2192.
Edit Profile